Plaquenil Shortage: What Providers and Prescribers Need to Know in 2026

Hydroxychloroquine (Plaquenil) remains one of the most widely prescribed disease-modifying antirheumatic drugs (DMARDs) in the United States, with millions of prescriptions filled annually for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and related conditions. Localized supply disruptions—driven by manufacturer discontinuations, distributor-level gaps, and regional demand variability—continue to affect patient access in 2026. This clinical guide outlines the current situation and provides actionable strategies for prescribers managing affected patients.

Current Supply Situation (2026)

As of 2026, generic hydroxychloroquine sulfate 200 mg tablets are available from several manufacturers, including Dr. Reddy's Laboratories, Amneal Pharmaceuticals, and Mylan (Viatris). Brand-name Plaquenil (Concordia Pharmaceuticals) continues to be manufactured and available through retail channels. However, several manufacturers have discontinued production—including Sun Pharma and specific Teva NDCs—reducing the total number of active manufacturers in the market.

The ASHP Drug Shortage database has documented multiple manufacturer-level disruptions over the past several years. While no active FDA-designated nationwide shortage existed at the time of publication, prescribers should be aware that patients may face localized supply gaps depending on their pharmacy's distributor relationships.

Pharmacokinetic Considerations for Dosing Interruptions

Hydroxychloroquine has a remarkably long elimination half-life—approximately 40 to 50 days following chronic administration, with some reports of whole-blood half-lives exceeding 100 days. This pharmacokinetic property has important implications for managing short-term supply interruptions:

• Short interruptions of 1–2 weeks are unlikely to produce measurable clinical consequences given extensive tissue stores
• Interruptions of 4+ weeks may increase flare risk in SLE patients, particularly those with active disease or a history of frequent flares
• Reloading (starting at the initial higher dose) after a prolonged interruption should be discussed on an individual basis
• Document any interruptions and adjust monitoring accordingly upon resumption

Clinical Priority Framework: Who Needs Priority Access?

When supply is constrained, consider stratifying your patient panel by clinical urgency:

• Highest priority: SLE patients with active disease, recent flares, lupus nephritis, or cardiopulmonary involvement. HCQ discontinuation in this group carries significant risk of organ damage.
• High priority: SLE patients in sustained remission who remain at high risk for flare. Also RA patients with moderate-to-severe disease who rely on HCQ as a component of combination DMARD therapy.
• Moderate priority: RA patients in clinical remission on HCQ monotherapy. A short interruption may be manageable with close monitoring.

Pharmacist Coordination Strategies

Direct engagement with pharmacists can significantly improve patient access:

• Ask your practice's preferred pharmacy to identify which specific manufacturer's stock they currently carry, and request that they maintain adequate inventory for your patient panel
• Write prescriptions as "Dispense As Written" (DAW) for specific manufacturer versions if a patient tolerates one manufacturer's inactive ingredients better than another's
• Consider routing high-risk patients to a compounding pharmacy that can prepare hydroxychloroquine suspensions or capsules if tablet supply is unavailable (requires a valid prescription)
• Direct patient to medfinder.com, a service that calls pharmacies on behalf of patients to identify which ones have the medication in stock

Prescribing for 90-Day Supplies

Hydroxychloroquine is not a controlled substance, so there are no DEA-imposed restrictions on prescribing quantity. Writing for a 90-day supply through mail-order can significantly reduce the frequency at which patients face supply gaps. Most insurance plans cover 90-day supplies for maintenance medications. Ensure prior authorization is in place where required by the patient's plan.

Considering Alternatives: Clinical Guidance

When supply interruptions are expected to exceed 4 weeks, consider the following therapeutic alternatives based on indication:

For RA: The ACR strongly recommends methotrexate as first-line DMARD therapy for moderate-to-severe RA. Sulfasalazine is recommended as the primary conventional DMARD alternative to HCQ for low disease activity RA. Leflunomide is a third-line option when methotrexate is contraindicated.

For SLE: No DMARD fully replaces HCQ in lupus management. Short-term corticosteroids may bridge an acute flare risk period. Belimumab (Benlysta) is approved for active SLE in patients already on standard therapy and may be considered in combination. Methotrexate or mycophenolate may address specific organ manifestations but lack HCQ's broad protective effects.

How medfinder Supports Your Patients

medfinder is a service that calls pharmacies on behalf of patients to identify which ones currently have specific medications—like hydroxychloroquine—in stock. Results are texted directly to the patient, eliminating hours of phone calls. You can direct patients to medfinder.com/providers to learn how to use the service and share it with their provider teams.